Literature DB >> 19255112

The evolution of influenza resistance and treatment.

David M Weinstock, Gianna Zuccotti.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19255112     DOI： 10.1001/jama.2009.324

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  40 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Suppression of influenza A virus replication in human lung epithelial cells by noncytotoxic concentrations bafilomycin A1.

Authors:  Behzad Yeganeh; Saeid Ghavami; Andrea L Kroeker; Thomas H Mahood; Gerald L Stelmack; Thomas Klonisch; Kevin M Coombs; Andrew J Halayko
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-10-31       Impact factor: 5.464

3.  The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.

Authors:  Wai Lan Wu; Siu-Ying Lau; Yixin Chen; Genyan Wang; Bobo Wing-Yee Mok; Xi Wen; Pui Wang; Wenjun Song; Tianwei Lin; Kwok-Hung Chan; Kwok-Yung Yuen; Honglin Chen
Journal:  Antiviral Res       Date:  2011-11-25       Impact factor: 5.970

Review 4.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

5.  Mechanism of inactivation of influenza viruses by immobilized hydrophobic polycations.

Authors:  Bryan B Hsu; Sze Yinn Wong; Paula T Hammond; Jianzhu Chen; Alexander M Klibanov
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

6.  In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Authors:  Katrina Sleeman; Vasiliy P Mishin; Varough M Deyde; Yousuke Furuta; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 7.  Evolution in health and medicine Sackler colloquium: a public choice framework for controlling transmissible and evolving diseases.

Authors:  Benjamin M Althouse; Theodore C Bergstrom; Carl T Bergstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

8.  [Use of antivirals in influenza pandemics].

Authors:  Eduard Diogène Fadini; Dolores Rodríguez Cumplido; Montserrat Bosch Ferrer
Journal:  Aten Primaria       Date:  2009-11-25       Impact factor: 1.137

9.  Novel genotyping and quantitative analysis of neuraminidase inhibitor resistance-associated mutations in influenza a viruses by single-nucleotide polymorphism analysis.

Authors:  Susu Duan; David A Boltz; Jiang Li; Christine M Oshansky; Henju Marjuki; Subrata Barman; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

10.  Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring.

Authors:  Elena A Govorkova; Tatiana Baranovich; Patrick Seiler; Jianling Armstrong; Andrew Burnham; Yi Guan; Malik Peiris; Richard J Webby; Robert G Webster
Journal:  Antiviral Res       Date:  2013-02-28       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.